Niraparib Shows Promise in Extending Progression-Free Survival in Epithelial Ovarian Cancer
• Niraparib monotherapy extends real-world progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC).
• Patients with homologous recombination-deficient (HRd) tumors, particularly those with BRCA-mutated tumors, experienced longer rwPFS and rwTTNT.
• Niraparib demonstrates clinical benefit in stage III EOC patients with no visible residual disease (NVRD) after primary cytoreductive surgery (PCS).
• Niraparib stands out among PARP inhibitors for its broad frontline maintenance therapy approval in EOC, regardless of BRCA mutation or HRD status.
Neoadjuvant Chemotherapy Now Dominant Initial Treatment for Advanced Ovarian Cancer
• Neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) has surpassed primary cytoreductive surgery (PCS) as the leading initial treatment for advanced epithelial ovarian cancer (EOC) in 2021.
• Analysis of the National Cancer Database (2010-2021) reveals a significant decline in PCS use, dropping from 70.1% to 37.2%, while ICS utilization increased from 16.6% to 40.8%.
• The shift towards NACT-ICS is observed across all stages and ages, suggesting a change in treatment preferences, potentially driven by reduced operative morbidity and mortality.
• The COVID-19 pandemic and associated limitations in operating room capabilities may have further accelerated the adoption of NACT followed by ICS for advanced EOC.
Novel Pan-Immune-Inflammation Nomogram Shows Promise in Predicting Epithelial Ovarian Cancer Outcomes
• A new predictive model based on pan-immune-inflammation value (PIV) demonstrates strong accuracy in forecasting survival outcomes for epithelial ovarian cancer patients, with distinct differences between high and low PIV groups.
• The study analyzed 576 Chinese patients, revealing significant survival differences - patients with low PIV showed better 3-year survival rates (76.71%) compared to those with high PIV (61.34%).
• The nomogram successfully predicted both overall survival and progression-free survival, with area under the curve values reaching up to 0.839 in the training cohort.
Radium-223 Plus Enzalutamide Improves Survival in mCRPC with Bone Metastases
• The PEACE-3 trial demonstrated that adding Radium-223 to enzalutamide significantly improved radiographic progression-free survival (rPFS) in mCRPC patients with bone metastases.
• The combination therapy also led to a statistically significant improvement in overall survival (OS) compared to enzalutamide alone, with a manageable safety profile.
• Time to next systemic treatment was significantly prolonged with the combination, suggesting a potential new first-line treatment option.
• The study mandated bone-protecting agents, highlighting their importance in managing bone health in patients receiving this combination therapy.
© Copyright 2025. All Rights Reserved by MedPath